Ningbo Sanxing Medical Electric Co (601567) Q2 2025 earnings summary

Executive summary

• Achieved revenue of ¥7.97 billion, up 13.93% year-over-year; net profit attributable to shareholders was ¥1.23 billion, up 6.93% year-over-year.

• Overseas business revenue grew 50.89% year-over-year, with significant breakthroughs in Europe, Middle East, and Latin America.

• Medical services segment faced policy pressure but continued to expand, with 38 hospitals and over 10,000 beds.

• In-hand orders reached ¥17.63 billion, up 18.39% year-over-year; overseas power distribution orders up 123.96%.

Financial highlights

• Operating income: ¥7.97 billion (+13.93% YoY); net profit attributable to shareholders: ¥1.23 billion (+6.93% YoY).

• Net profit after non-recurring items: ¥1.14 billion (+5.34% YoY).

• Basic and diluted EPS: ¥0.87 (+7.41% YoY); net assets per share: ¥8.68.

• Operating cash flow: -¥59.26 million (down from +¥260.24 million YoY).

• Gross margin: 28.97%; R&D investment: ¥256.65 million (3.22% of revenue).

Outlook and guidance

• Continued focus on global expansion and new energy; expects stable growth in both smart power and medical segments.

• 2025-2027 annual cash dividend payout ratio planned at no less than 45%.